Receptor Binding Affinities of Synthetic Cannabinoids Determined by Non-Isotopic Receptor Binding Assay |
Cha, Hye Jin
(Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Song, Yun Jeong (Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) Lee, Da Eun (Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) Kim, Young-Hoon (Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) Shin, Jisoon (Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) Jang, Choon-Gon (Department of Pharmacology, School of Pharmacy, Sungkyunkwan University) Suh, Soo Kyung (Pharmacological Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) Kim, Sung Jin (Cosmetics Policy Division, Ministry of Food and Drug Safety) Yun, Jaesuk (Neuroimmunology Lab, College of Pharmacy, Wonkwang University) |
1 | Cooper, Z.D. (2016) Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal. Curr. Psych. Rep., 18, 52. DOI |
2 | Fattore, L. (2016) Synthetic cannabinoids - Further evidence supporting the relationship between cannabinoids and psychosis. Biol. Psych., 79, 539-548. DOI |
3 | Gray, R., Bressington, D., Hughes, E. and Ivanecka, A. (2016) A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness. J. Psych. Ment. Health Nurs., 23, 267-281. DOI |
4 | Springer, Y.P., Gerona, R., Scheunemann, E., Shafer, S.L., Lin, T., Banister, S.D. and McLaughlin, J.B. (2016) Increase in adverse reactions associated with use of synthetic cannabinoids - Anchorage, Alaska, 2015-2016. MMWR Morb. Mort. Wkly Rep., 65, 1108-1111. DOI |
5 | White, C.M. (2017) The pharmacologic and clinical effects of illicit synthetic cannabinoids. J. Clin. Pharmacol., 57, 297-304. DOI |
6 | Diez-Alarcia, R., Ibarra-Lecue, I., Lopez-Cardona, A.P., Meana, J., Gutierrez-Adan, A., Callado, L.F. and Uriguen, L. (2016) Biased agonism of three different cannabinoid receptor agonists in mouse brain cortex. Front. Pharmacol., 7, 415. |
7 | McPartland, J.M., Glass, M. and Pertwee, R.G. (2007) Metaanalysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br. J. Pharmacol., 152, 583-593. DOI |
8 | Layer, R.T. (2001) Saturation analysis of ligand binding using a centrifugation procedure. Curr. Protoc. Neurosci., 2, 7.7.1-7.7.4. DOI |
9 | Rossi, A.M. and Taylor, C.W. (2013) High-throughput fluorescence polarization assay of ligand binding to receptors. Cold Spring Harb. Prot., 2013, 938-946. |
10 | Martinez-Pinilla, E., Rabal, O., Reyes-Resina, I., Zamarbide, M., Navarro, G., Sanchez-Arias, J.A. and Franco, R. (2016) Two affinity sites of the cannabinoid subtype 2 receptor identified by a novel homogeneous binding assay. J. Pharmacol. Exp. Ther., 358, 580-587. DOI |
11 | Hoa, X.D., Kirk, A.G. and Tabrizian, M. (2007) Towards integrated and sensitive surface plasmon resonance biosensors: a review of recent progress. Biosens. Bioelectron., 23, 151-160. DOI |
12 | Myint, K.Z. and Xie, X.Q. (2015) Ligand biological activity predictions using fingerprint-based artificial neural networks (FANN-QSAR). Methods Mol. Biol., 1260, 149-164. DOI |
13 | Piliarik, M., Vaisocherova, H. and Homola, J. (2009) Surface plasmon resonance biosensing. Methods Mol. Biol., 503, 65-88. DOI |
14 | Cha, H.J., Lee, K., Song, M., Hyeon, Y., Hwang, J., Jang, C. and Jeong, H. (2014) Dependence potential of the synthetic cannabinoids JWH-073, JWH-081, and JWH-210: In vivo and in vitro approaches. Biomol. Ther. (Seoul), 22, 363-369. DOI |
15 | Mella-Raipan, J., Hernandez-Pino, S., Morales-Verdejo, C. and Pessoa-Mahana, D. (2014) 3D-QSAR/CoMFA-based structure-affinity/selectivity relationships of aminoalkylindoles in the cannabinol and receptors. Molecules, 19, 2842-2861. DOI |
16 | Cereghino, J.L. and Cregg, J.M. (2000) Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol. Rev., 24, 45-66. DOI |
17 | Reilander, H. and Weiss, H.M. (1998) Production of G-protein-coupled receptors in yeast. Curr. Opin. Biotechnol., 9, 510-517. DOI |
18 | Smoum, R., Baraghithy, S., Chourasia, M., Breuer, A., Mussai, N., Nttar-Namdar, M. and Bab, I. (2015) cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency. Proc. Natl. Acad. Sci. U.S.A., 112, 8774-8779. DOI |
19 | Kim, T.K., Zhang, R., Feng, W., Cai, J., Pierce, W. and Song, Z.H. (2005) Expression and characterization of human cannabinoid receptor in methylotrophic yeast Pichia pastoris. Protein. Expr. Purif., 40, 60-70. DOI |
20 | Presley, C.S., Abidi, A.H. and Moore, B.M., 2nd. (2016) Cannabinoid receptor 1 ligands revisited: Pharmacological assessment in the ACTOne system. Anal. Biochem., 498, 8-28. DOI |
21 | Tournebize, J., Gibaja, V. and Kahn, J.P. (2016) Acute effects of synthetic cannabinoids: update 2015. Subst. Abuse, 11, 1-23. |
22 | Wiley, J.L., Marusich, J.A., Lefever, T.W., Antonazzo, K.R., Wallgren, M.T., Cortes, R.A. and Thomas, B.F. (2015) ABCHMINACA, AB-PINACA, and FUBIMINA: Affinity and potency of novel synthetic cannabinoids in producing -tetrahydrocannabinol-like effects in mice. J. Pharmacol. Exp. Ther., 354, 328-339. DOI |
23 | Cha, H.J., Lee, K., Song, M., Hyeon, Y., Hwang, J., Jang, C., Ahn, J., Jeon, S., Kim, H., Kim, Y., Seong, W., Kang, H., Yoo, H.S. and Jeong, H. (2014) Dependence potential of the synthetic cannabinoids JWH-073, JWH-081, and JWH-210: in vivo and in vitro approaches. Biomol. Ther. (Seoul), 22, 363-369. DOI |
24 | Roche, J.P., Bounds, S., Brown, S. and Mackie, K. (1999) A mutation in the second transmembrane region of the receptor selectively disrupts G protein signaling and prevents receptor internalization. Mol. Cell. Pharmacol., 56, 611-618. DOI |
25 | Karila, L., Benyaminia, A., Blecha, L., Cottencin, O. and Billieux, J. (2016) The synthetic cannabinoids phenomenon. Curr. Pharm. Des., 22, 6420-6425. DOI |
26 | Scocard, A., Benyamina, A., Coscas, S. and Karila, L. (2017) Synthetic cannabinoids: A new addiction matrix. Pres. Med., 46, 11-22. DOI |
27 | Paulke, A., Proschak, E., Sommer, K., Achenbach, J., Wunder, C. and Toennes, S.W. (2016) Synthetic cannabinoids: In silico prediction of the cannabinoid receptor 1 affinity by a quantitative structure-activity relationship model. Toxicol. Lett., 245, 1-6. DOI |
28 | Maida, V. and Daeninck, P.J. (2016) A user's guide to cannabinoid therapies in oncology. Curr. Oncol., 23, 398-406. DOI |
29 | Androvicova, R., Horacek, J., Stark, T., Drago, F. and Micale, V. (2017) Endocannabinoid system in sexual motivational processes: Is it a novel therapeutic horizon? Pharmacol. Res., 115, 200-208. DOI |
30 | Ford, B.M., Tai, S., Fantegrossi, W.E. and Prather, P.L. (2017) Synthetic pot: not your grandfather's marijuana. Trend. Pharmacol. Sci., 38, 257-276. DOI |